{
  "id": "lab-quiz3-antilipemics",
  "title": "Lab Quiz 3 — Antilipemics",
  "pools": {
    "easy": [
      {
        "type": "mcq",
        "prompt": "Atorvastatin belongs to which class?",
        "choices": [
          "Statin (HMG‑CoA reductase inhibitor)",
          "Fibrate",
          "Bile acid sequestrant",
          "Omega‑3 fatty acid"
        ],
        "answer": "Statin (HMG‑CoA reductase inhibitor)",
        "explain": "Atorvastatin is a statin."
      },
      {
        "type": "mcq",
        "prompt": "Ezetimibe is best categorized as:",
        "choices": [
          "Cholesterol absorption inhibitor",
          "PCSK9 inhibitor",
          "Fibrate",
          "Niacin"
        ],
        "answer": "Cholesterol absorption inhibitor",
        "explain": "Blocks intestinal NPC1L1 transporter."
      },
      {
        "type": "mcq",
        "prompt": "Fenofibrate belongs to which class?",
        "choices": [
          "Fibrate",
          "Statin",
          "Bile acid sequestrant",
          "Ezetimibe"
        ],
        "answer": "Fibrate",
        "explain": "Fenofibrate is a PPAR‑α agonist."
      },
      {
        "type": "mcq",
        "prompt": "Which drug is a PCSK9 monoclonal antibody?",
        "choices": [
          "Alirocumab",
          "Bempedoic acid",
          "Ezetimibe",
          "Cholestyramine"
        ],
        "answer": "Alirocumab",
        "explain": "Alirocumab and evolocumab are PCSK9 mAbs."
      },
      {
        "type": "mcq",
        "prompt": "Icosapent ethyl (Vascepa) is:",
        "choices": [
          "EPA omega‑3 fatty acid",
          "Fibrate",
          "Statin",
          "Bile acid sequestrant"
        ],
        "answer": "EPA omega‑3 fatty acid",
        "explain": "Purified EPA used primarily for triglyceride lowering and CV risk reduction in select patients."
      },
      {
        "type": "mcq",
        "prompt": "Cholestyramine is a:",
        "choices": [
          "Bile acid sequestrant",
          "Statin",
          "PCSK9 inhibitor",
          "Fibrate"
        ],
        "answer": "Bile acid sequestrant",
        "explain": "Binds bile acids in the gut to lower LDL."
      },
      {
        "type": "mcq",
        "prompt": "Bempedoic acid is classified as a(n):",
        "choices": [
          "ATP‑citrate lyase inhibitor",
          "Cholesterol absorption inhibitor",
          "Fibrate",
          "Niacin"
        ],
        "answer": "ATP‑citrate lyase inhibitor",
        "explain": "Acts upstream of HMG‑CoA reductase in the liver."
      },
      {
        "type": "mcq",
        "prompt": "Which statin brand/generic pair is correct?",
        "choices": [
          "Lipitor — atorvastatin",
          "Crestor — simvastatin",
          "Zocor — rosuvastatin",
          "Pravachol — fluvastatin"
        ],
        "answer": "Lipitor — atorvastatin",
        "explain": "Crestor = rosuvastatin; Zocor = simvastatin; Pravachol = pravastatin."
      },
      {
        "type": "mcq",
        "prompt": "Which is a bile acid sequestrant?",
        "choices": [
          "Colesevelam",
          "Ezetimibe",
          "Niacin",
          "Icosapent ethyl"
        ],
        "answer": "Colesevelam",
        "explain": "BAS: cholestyramine, colestipol, colesevelam."
      },
      {
        "type": "mcq",
        "prompt": "Which statin is generally considered more potent per mg?",
        "choices": [
          "Rosuvastatin",
          "Pravastatin",
          "Fluvastatin",
          "Lovastatin"
        ],
        "answer": "Rosuvastatin",
        "explain": "Rosuvastatin and atorvastatin are most potent."
      },
      {
        "type": "mcq",
        "prompt": "Gemfibrozil belongs to which class?",
        "choices": [
          "Fibrate",
          "Niacin",
          "Omega‑3 fatty acid",
          "Statin"
        ],
        "answer": "Fibrate",
        "explain": "A fibrate; avoid with many statins due to myopathy risk."
      },
      {
        "type": "mcq",
        "prompt": "Colestipol is a:",
        "choices": [
          "Bile acid sequestrant",
          "PCSK9 inhibitor",
          "Statin",
          "Ezetimibe"
        ],
        "answer": "Bile acid sequestrant",
        "explain": "BAS: cholestyramine, colestipol, colesevelam."
      },
      {
        "type": "mcq",
        "prompt": "Inclisiran is best described as:",
        "choices": [
          "siRNA that lowers hepatic PCSK9",
          "PCSK9 monoclonal antibody",
          "Bile acid sequestrant",
          "Fibrate"
        ],
        "answer": "siRNA that lowers hepatic PCSK9",
        "explain": "Inclisiran reduces PCSK9 synthesis via RNA interference."
      },
      {
        "type": "mcq",
        "prompt": "Which is a high‑intensity statin dose?",
        "choices": [
          "Atorvastatin 40–80 mg",
          "Simvastatin 20 mg",
          "Pravastatin 40 mg",
          "Lovastatin 40 mg"
        ],
        "answer": "Atorvastatin 40–80 mg",
        "explain": "High‑intensity: atorvastatin 40–80 mg or rosuvastatin 20–40 mg."
      },
      {
        "type": "mcq",
        "prompt": "Crestor is the brand name for:",
        "choices": [
          "Rosuvastatin",
          "Simvastatin",
          "Atorvastatin",
          "Pitavastatin"
        ],
        "answer": "Rosuvastatin",
        "explain": "Crestor = rosuvastatin."
      },
      {
        "type": "mcq",
        "prompt": "Zetia is the brand name for:",
        "choices": [
          "Ezetimibe",
          "Bempedoic acid",
          "Gemfibrozil",
          "Colesevelam"
        ],
        "answer": "Ezetimibe",
        "explain": "Zetia = ezetimibe."
      },
      {
        "type": "mcq",
        "prompt": "Repatha is the brand for:",
        "choices": [
          "Evolocumab",
          "Alirocumab",
          "Inclisiran",
          "Niacin"
        ],
        "answer": "Evolocumab",
        "explain": "Repatha = evolocumab (PCSK9 mAb)."
      },
      {
        "type": "mcq",
        "prompt": "Praluent is the brand for:",
        "choices": [
          "Alirocumab",
          "Evolocumab",
          "Ezetimibe",
          "Fenofibrate"
        ],
        "answer": "Alirocumab",
        "explain": "Praluent = alirocumab (PCSK9 mAb)."
      },
      {
        "type": "tf",
        "prompt": "Niacin commonly causes flushing.",
        "answer": "True",
        "explain": "Flushing is a classic effect of niacin."
      },
      {
        "type": "tf",
        "prompt": "Bile acid sequestrants often cause constipation or GI upset.",
        "answer": "True",
        "explain": "GI issues are common with BAS."
      }
    ],
    "hard": [
      {
        "type": "mcq",
        "prompt": "Statins reduce cholesterol by inhibiting which enzyme?",
        "choices": [
          "HMG‑CoA reductase",
          "Squalene synthase",
          "ATP‑citrate lyase",
          "NPC1L1"
        ],
        "answer": "HMG‑CoA reductase",
        "explain": "Rate‑limiting step in cholesterol synthesis."
      },
      {
        "type": "mcq",
        "prompt": "Which pairing is most prone to myopathy risk?",
        "choices": [
          "Ezetimibe + BAS",
          "Gemfibrozil + statin",
          "Fenofibrate + omega‑3",
          "Niacin + ezetimibe"
        ],
        "answer": "Gemfibrozil + statin",
        "explain": "Gemfibrozil inhibits statin glucuronidation."
      },
      {
        "type": "mcq",
        "prompt": "Ezetimibe targets:",
        "choices": [
          "NPC1L1 transporter",
          "PCSK9 protein",
          "LDL receptor",
          "CETP"
        ],
        "answer": "NPC1L1 transporter",
        "explain": "Blocks cholesterol absorption at the brush border."
      },
      {
        "type": "mcq",
        "prompt": "Bempedoic acid primarily acts in which tissue?",
        "choices": [
          "Hepatocytes",
          "Skeletal muscle",
          "Adipose tissue",
          "Intestinal mucosa"
        ],
        "answer": "Hepatocytes",
        "explain": "Activated in the liver; minimal muscle exposure."
      },
      {
        "type": "mcq",
        "prompt": "Inclisiran maintenance dosing after initial 0 and 3‑month injections is:",
        "choices": [
          "Every 6 months",
          "Monthly",
          "Every 3 months",
          "Annually"
        ],
        "answer": "Every 6 months",
        "explain": "After day 0 and 3 months, give every 6 months."
      },
      {
        "type": "mcq",
        "prompt": "Which lipid effect profile matches fibrates?",
        "choices": [
          "↓TG greatly; ↑HDL modestly; LDL variable",
          "↓LDL greatly; no HDL change; ↓TG none",
          "↑HDL greatly; ↑LDL greatly; ↓TG modestly",
          "↓TG none; ↑HDL greatly; ↓LDL modestly"
        ],
        "answer": "↓TG greatly; ↑HDL modestly; LDL variable",
        "explain": "Signature fibrate profile."
      },
      {
        "type": "mcq",
        "prompt": "Which monitoring is most relevant at statin initiation?",
        "choices": [
          "Baseline ALT/AST",
          "Serum uric acid",
          "INR",
          "TSH"
        ],
        "answer": "Baseline ALT/AST",
        "explain": "Baseline hepatic function typically assessed."
      },
      {
        "type": "mcq",
        "prompt": "Which condition is a relative contraindication to bile acid sequestrants?",
        "choices": [
          "Severe hypertriglyceridemia",
          "Hypertension",
          "Mild CKD",
          "Hypothyroidism"
        ],
        "answer": "Severe hypertriglyceridemia",
        "explain": "BAS can raise triglycerides."
      },
      {
        "type": "mcq",
        "prompt": "Which statement best describes EPA‑only therapy (icosapent ethyl)?",
        "choices": [
          "Shown to reduce CV events in select high‑risk patients on statins",
          "Always raises LDL significantly",
          "First‑line LDL‑lowering monotherapy",
          "Inhibits PCSK9"
        ],
        "answer": "Shown to reduce CV events in select high‑risk patients on statins",
        "explain": "Evidence supports CV risk reduction in specific populations."
      },
      {
        "type": "mcq",
        "prompt": "Which statin is least dependent on CYP3A4 metabolism?",
        "choices": [
          "Pravastatin",
          "Simvastatin",
          "Lovastatin",
          "Atorvastatin"
        ],
        "answer": "Pravastatin",
        "explain": "Pravastatin has minimal CYP3A4 metabolism."
      },
      {
        "type": "mcq",
        "prompt": "Which bile acid sequestrant may improve glycemic control in diabetes?",
        "choices": [
          "Colesevelam",
          "Cholestyramine",
          "Colestipol",
          "Ezetimibe"
        ],
        "answer": "Colesevelam",
        "explain": "Colesevelam can modestly improve glycemic control."
      },
      {
        "type": "mcq",
        "prompt": "Which adverse effect is most typical with niacin therapy?",
        "choices": [
          "Flushing",
          "Constipation",
          "Cough",
          "Pedal edema"
        ],
        "answer": "Flushing",
        "explain": "Prostaglandin‑mediated flushing is characteristic."
      },
      {
        "type": "mcq",
        "prompt": "Which combination increases risk of bradycardia/heart block the least?",
        "choices": [
          "Metoprolol + diltiazem",
          "Statin + gemfibrozil",
          "Ezetimibe + statin",
          "Niacin + BAS"
        ],
        "answer": "Niacin + BAS",
        "explain": "The others listed have known interaction risks (notably statin+gemfibrozil)."
      },
      {
        "type": "mcq",
        "prompt": "Which agent most directly increases hepatic LDL receptor availability?",
        "choices": [
          "PCSK9 inhibitors",
          "Niacin",
          "Omega‑3 fatty acids",
          "BAS"
        ],
        "answer": "PCSK9 inhibitors",
        "explain": "They prevent LDL receptor degradation."
      },
      {
        "type": "short",
        "prompt": "Name one PCSK9 monoclonal antibody.",
        "answerText": [
          "alirocumab",
          "evolocumab"
        ],
        "explain": "PCSK9 mAbs include alirocumab and evolocumab."
      },
      {
        "type": "short",
        "prompt": "Name one bile acid sequestrant.",
        "answerText": [
          "cholestyramine",
          "colestipol",
          "colesevelam"
        ],
        "explain": "Any of these BAS is correct."
      },
      {
        "type": "short",
        "prompt": "Name one high‑intensity statin (drug name only).",
        "answerText": [
          "atorvastatin",
          "rosuvastatin"
        ],
        "explain": "Atorvastatin or rosuvastatin qualify at specific doses."
      },
      {
        "type": "tf",
        "prompt": "Ezetimibe inhibits HMG‑CoA reductase.",
        "answer": "False",
        "explain": "It blocks NPC1L1; statins inhibit HMG‑CoA reductase."
      },
      {
        "type": "tf",
        "prompt": "Gemfibrozil is generally preferred over fenofibrate when combined with statins.",
        "answer": "False",
        "explain": "Gemfibrozil has higher myopathy risk with statins; fenofibrate is generally preferred if a fibrate must be used."
      },
      {
        "type": "tf",
        "prompt": "Bempedoic acid can increase uric acid and has tendon‑related warnings.",
        "answer": "True",
        "explain": "Hyperuricemia and rare tendon issues have been reported."
      }
    ]
  }
}